NCT01696500: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. |
|
|
| Completed | 3 | 10 | Japan | Intravenous immunoglobulin | Nihon Pharmaceutical Co., Ltd | Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | 06/14 | 06/14 | | |